| GFAP — Glial Fibrillary Acidic Protein | |
|---|---|
| Symbol | GFAP |
| Full Name | Glial Fibrillary Acidic Protein |
| Chromosome | 17q21.31 |
| NCBI Gene | 2670 |
| Ensembl | ENSG00000131095 |
| OMIM | 137780 |
| UniProt | P14136 |
| Diseases | Alexander Disease, Alzheimer's Disease (biomarker), Multiple Sclerosis (biomarker) |
| Expression | Astrocytes, Schwann cells, Enteric glia |
Gfap (Glial Fibrillary Acidic Protein Gene) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[GFAP[/entities/glial-fibrillary-acidic-protein encodes the glial fibrillary acidic protein, a type III intermediate filament protein that is the canonical marker of [astrocytes[/cell-types/astrocytes in the central nervous system. The gene is located on chromosome 17q21.31, spans approximately 10 kb, and contains 9 exons encoding a 432-amino acid protein of ~50 kDa.[1]
[GFAP[/entities/glial-fibrillary-acidic-protein has dual significance in neurodegenerative disease. First, dominant gain-of-function mutations in [GFAP[/entities/glial-fibrillary-acidic-protein cause [Alexander disease[/diseases/alexander-disease — a rare, progressive leukodystrophy
characterized by [GFAP protein[/proteins/gfap aggregation into Rosenthal fibers and severe astrocyte dysfunction.[2] Over 550 pathogenic [GFAP[/entities/gfap variants have been cataloged, with a 2024 systematic review showing that arginine
substitutions are the most frequent disease-causing mutations.[3] Second, GFAP released from [reactive astrocytes[/cell-types/reactive-astrocytes-a2 into blood has
become one of the most promising plasma biomarkers for [Alzheimer's disease[/diseases/alzheimers, detectable years before symptom onset and now incorporated into the 2024 updated NIA-AA diagnostic
criteria as an inflammatory/immune process biomarker reflecting astrocyte reactivity.10,11
The [GFAP protein[/proteins/gfap is the principal intermediate filament in [astrocytes[/cell-types/astrocytes:
GFAP generates at least 10 isoforms through alternative splicing:
The ratio of GFAPδ to GFAPα influences filament network properties — increased GFAPδ disrupts normal filament assembly and is altered in [aging] and AD. GFAPδ-enriched [astrocytes[/cell-types/astrocytes are found preferentially in the neurogenic subventricular zone and may serve as neural stem cells.[6]
GFAP is expressed in all astrocyte subtypes but with regional variation:
[Alexander disease[/diseases/alexander-disease (OMIM #203450) is caused by heterozygous dominant gain-of-function GFAP mutations and is the only known human disease caused by mutation of an intermediate filament gene in astrocytes.
Mutation spectrum: A 2024 meta-analysis identified 550+ predominantly missense variants, with hotspots at:[3]
| Residue | Exon | Frequency | Clinical Form |
|---|---|---|---|
| R79 (R79C, R79H, R79L) | Exon 1 | ~7% of all variants | Infantile, juvenile |
| R88 (R88C, R88S) | Exon 1 | ~5% | Infantile |
| R239 (R239C, R239H, R239P) | Exon 4 | ~12% (most common) | Infantile — typically severe |
| R416 (R416W) | Exon 8 | ~3% | Adult-onset |
Pathogenic mechanism: Mutant GFAP disrupts filament assembly, triggering a cascade of astrocyte dysfunction:
Clinical subtypes:
A 2025 study using a GFAP R237H knock-in rat model demonstrated that GFAP mutation leads to a neurodegenerative profile with impaired synaptic plasticity and cognitive deficits, establishing that astrocyte dysfunction alone — without primary neuronal mutation — can drive neurodegeneration.[11]
While GFAP coding variants are not a major genetic risk factor for AD, the gene's product serves as a critical fluid biomarker:
Preclinical detection: Plasma [GFAP[/proteins/gfap is elevated 10+ years before AD symptom onset in amyloid-positive individuals, making it one of the earliest blood-based markers of AD pathology.[7] The elevation reflects [reactive astrogliosis[/mechanisms/reactive-astrogliosis surrounding [amyloid plaques].
Clinical trial enrichment: A 2025 study demonstrated that using both plasma GFAP and amyloid PET to select cognitively unimpaired individuals would significantly reduce the required sample size for clinical trials in preclinical AD, lowering overall costs by enabling better identification of individuals likely to show progression.[9]
Disease stratification: Plasma [p-tau217[/entities/p-tau217, GFAP, and [NfL[/proteins/nfl-protein together enable disease stratification, with GFAP mediating the early association between amyloid pathology and downstream tau] propagation.[10] Notably, [Aβ[/entities/amyloid-beta-induced tau] progression occurred only in individuals with abnormally high GFAP, suggesting astrocyte reactivity acts as a necessary co-factor for disease progression.
NIA-AA criteria: GFAP is classified as an inflammatory/immune process biomarker (category "I") in the 2024 updated NIA-AA diagnostic framework, specifically reflecting the astrocyte reactivity subcategory.
In the Allen Human Brain Atlas:
GFAP expression follows a characteristic developmental trajectory: absent in early embryonic brain, first detectable during late gestation as radial glia begin differentiating into astrocytes, then increasing postnatally as astrocyte maturation proceeds. Expression persists throughout adulthood and increases with normal aging, particularly in white matter tracts.
The study of Gfap (Glial Fibrillary Acidic Protein Gene) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.